DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Society for Investigational Dermatology (“SID”) virtual meeting May 3-8, 2021. DermTech’s chief scientific officer, Michael Howell, PhD, presented research titled, “Non‑Invasively Stratifying Atopic Dermatitis Patients Based on Inflammatory Genes” during the concurrent Patient-Targeted Research Mini-Symposia.

This research study demonstrates the utility of DermTech’s non-invasive skin sampling platform technology to stratify Atopic Dermatitis (“AD”) patients based on their dominant inflammatory signature and suggests the incorporation of this clinically valuable technique in the personalized treatment of AD patients with targeted therapies. The presentation also highlighted that while there are a growing number of targeted therapies in clinical development, such therapies have been shown to be effective in less than 50% of patients in those studies. To further this research, DermTech has initiated a prospective sample collection study to evaluate the effectiveness of biologic treatments by analyzing genomic biomarkers and microbiome information from pediatric and adult subjects with AD (NCT04699695).

“Atopic dermatitis is a chronic skin disease that affects up to 10% of the global population. Despite an increase in the number of approved therapies, a substantial portion of AD patients are not adequately treated with approved therapies. Incorporating non-invasive skin sampling into clinical studies provides the opportunity to improve our understanding of disease pathogenesis without the need for biopsies and to delineate more personalized approaches for the treatment of AD,” commented Michael Howell, Ph.D., DermTech’s chief scientific officer.

Dr. Howell serves as a scientific program committee member of the SID and his presentation will be available for viewing on-demand from May 3, 2021 to May 31, 2021.

The full presentation can be found here: www.dermtech.com/hcp/collaborations.

The SID’s mission is to advance the sciences relevant to skin disease through education, advocacy and scholarly exchange of scientific information. For more information about the SID, please visit: www.sidnet.org.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.